At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses interim results from KEYNOTE-028, a phase 1b clinical trial that was designed to evaluate the antitumour activity and safety of pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with PD-L1-positive nasopharyngeal carcinoma.
KEYNOTE-028: Phase 1b trial of pembrolizumab in PD-L1-positive nasopharyngeal carcinoma
5th February 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now